Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD

Brian J. Lipworth (Lead / Corresponding author), Chris R. W. Kuo

    Research output: Contribution to journalLetterpeer-review

    1 Citation (Scopus)
    61 Downloads (Pure)


    The pooled post hoc analysis of three randomised controlled trials by Vestbo et al. [1] found that combinations containing inhaled corticosteroid (ICS) significantly reduced non-respiratory-related mortality in chronic obstructive pulmonary disease (COPD) compared to long-acting bronchodilator therapies alone, the difference amounting to −35% (95% CI −57% to −3%). These studies did not adjudicate on cause of death and only followed patients for up to 1 year. In the IMPACT trial, all-cause mortality was 42% lower and cardiovascular attributed deaths were 52% lower when comparing triple therapy to combined long-acting bronchodilators over 1 year [2].
    Original languageEnglish
    Article number1802420
    JournalEuropean Respiratory Journal
    Issue number2
    Publication statusPublished - 1 Feb 2019

    ASJC Scopus subject areas

    • Pulmonary and Respiratory Medicine


    Dive into the research topics of 'Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD'. Together they form a unique fingerprint.

    Cite this